Previous 10 | Next 10 |
San Francisco, California--(Newsfile Corp. - February 14, 2022) - Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Cla...
SAN FRANCISCO, CA / ACCESSWIRE / February 11, 2022 / Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ:RETA) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: ...
Plans to Complete Submission by the End of the First Quarter of 2022 If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich’s Ataxia Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Rea...
Biotech stocks have been hammered back to back for two years in a row now. The last time the SPDR ETF suffered a drop of 15% or more was in 2018, and the fund followed it up with a 33% increase in 2019. It dropped more than 15% in 2016 and followed that up with […] For further detail...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 16, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 4, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is...
Last week was an especially rough one for several small biotechs. Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE) , Bolt Biotherapeutics (NASDAQ: BOLT) , and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. stocks finished higher on Friday to close out one of the best weeks since February. Investors took in a consumer price index report that...
With the biggest ever intra-day loss, Reata Pharmaceuticals (RETA -46.1%) is trading at the lowest level since May 2018 after the efforts to introduce its first-ever commercialized product suffered a setback following a negative vote from an FDA expert panel. With the support of data fro...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...